Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
January 24, 2007

Pfizer Taps Medivas to Provide Delivery Methods for its Ophthalmic Compounds

  • MediVas and Pfizer will collaborate on R&D related to delivery methods for Pfizer compounds to treat eye diseases. By combining the fully biodegradable and biocompatible MediVas polymers with the Pfizer compounds, the companies hope to create a product that can change the paradigm of how ophthalmic treatments are administered.

    "We are confident that by combining Pfizer's compounds with our polymer delivery system we can help to increase patient compliance and significantly improve treatment of diseases of the eye,” remarks Kenneth W. Carpenter, MediVas' president and CEO.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.